Raymond J. March | Tuesday August 7, 2018 at 1:39 PM PDT
Off-label information policy reform works to broaden what information drug providers can share.
Shop at Amazon.com
By linking to Amazon.com from this page, the Independent Institute earns referral fees of 4% to 15% from whatever you buy. Bookmark the above link and you can support the Institute when you do your normal shopping!New Books
Free Shipping On Orders Over $60! (Within U.S.A.) 
GUN CONTROL IN NAZI-OCCUPIED FRANCE: Tyranny and Resistance
By Stephen P. Halbrook
T.R.M. HOWARD: Doctor, Entrepreneur, Civil Rights Pioneer
By David T. Beito, Linda Royster Beito
ELEVEN PRESIDENTS: Promises vs. Results in Achieving Limited Government
By Ivan Eland
POPE FRANCIS AND THE CARING SOCIETY
Edited By Robert M. Whaples
CHINA’S GREAT MIGRATION: How the Poor Built a Prosperous Nation
By Bradley M. Gardner
Tag: pharmaceutical regulations
John R. Graham | Tuesday October 4, 2016 at 5:01 PM PDT
The Goldwater Institute has had great success getting states to pass “Right to Try” laws. Right to Try allows a desperately sick patient to take an experimental new medicine before the FDA has approved it. Since I last wrote about this in May 2014, 31 states have passed Right to Try. Further, U.S. Senator...
Read More »
John R. Graham | Wednesday October 7, 2015 at 5:00 AM PDT
BloombergBusiness has another story of a jaw-dropping price hike for a very old medical. In this case, Colchicine, a gout remedy so old that the ancient Greeks knew about its effects, used to cost about 25 cents per pill in the U.S. Then in 2010 its price suddenly jumped 2,000 percent. How did this...
Read More »
